TherapeuticsMD, Inc., (TXMD) is a United States based women’s healthcare company. The products are designed to address the unique changes women experience through the various stages of their lives with main focus towards family planning, reproductive health, and menopause management. It offers products for the treatment of dyspareunia and vasomotor symptoms. The range of products also include contraceptive vaginal system, transdermal creams, prenatal vitamins and oral progesterone and estradiol formulations.
During the regular trading hours of December 10,2021, the stock of TherapeuticsMD, Inc., traded at $0.45 (3.30% decline). while at the time of writing, the after hours exhibited a sharp decline of 9.76% ($0.41).
Events and Happenings
December 10, 2021,TXMD announced that the FDA had given recommendations and asked for additional information regarding revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. The sNDA requested slight revisions to the in vitro release testing specification for ANNOVERA to allow for regular commercial manufacturing variation. TXMD submitted the revisions to allow it to efficiently and quickly surge the supply to meet expected patient demand for ANNOVERA.
On December 08, 2021, TXMD announced the settlement of the formerlyrevealed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals.As part of the settlement, Amnealwas granted a license from TXMD to commercialize Amneal’s generic version of BIJUVA (1 mg estradiol and 100 mg progesterone). It will be commencing on May 25, 2032, or earlier under certain circumstances customary for settlement agreements of this nature.
On November 11, 2021TherapeuticsMD, Inc., reported financial results for the third quarter ended September 30, 2021. Some of the significant features are
Total net revenue reported by the company for the duration of Q3 2021 was $25 million, while for the same quarter of 2020 it was reported to be 19 million. Total current assets of the TXMD were reported to be $159 million for third quarter 2021, while for Q3 2020, $122 million total current assets were reported.
Earnings per Share
Net loss for the Q3 2020 was reported to be $32.6 million, or $0.12 per basic and diluted shareas compared tonet loss for the same period of 2021, it was $47.4 million, or $0.11 per basic and diluted share.
As the company announced product upgradation and collaboration with AmnealPharmaceuticals, the stock price as predicted by the analysts may rise notably in the coming few days.